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Abstract
The novel coronavirus disease 2019 (COVID-19) outbreak places perinatal women at higher risk
of developing anxiety and depression. Uncertainty, fear, and confusion in medical, social,
economic, occupational and political aspects of life in the US add to existing stressors that
perinatal women experience. To optimize the quality of perinatal care during the pandemic,
appropriate mental health interventions must be implemented to prevent and alleviate perinatal
anxiety and depression and improve maternal and infant outcomes. Measures include increased
screening, non-pharmacologic and/or pharmacologic interventions and the use of telehealth for
care delivery.
Keywords: perinatal anxiety, perinatal depression, COVID-19, SARS CoV-2, maternal mental
health
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Introduction
Pregnancy is a complex and dynamic experience during which women go through drastic
physiological and psychological changes. These changes often place perinatal women at
increased risk of developing anxiety and depression.1 Approximately 20-30% of women
worldwide experience at least one psychiatric disorder during pregnancy or postpartum.2 About
13 to 21% of prenatal and 11-17% postpartum women experience anxiety and depression.3,4
Perinatal anxiety and depression (PAD) are associated with existing or a history of mental health
conditions, marital discord, stressful life events or environments, lack of social support, low
socioeconomic status as well as the general fear or diagnosis of adverse pregnancy outcomes
such as miscarriage, preterm delivery, low birth weight and adverse maternal health conditions.4
In addition to stressors that place perinatal women at risk for PAD, the current global
pandemic of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) has the potential
to increase the incidence of PAD. SARS-CoV2 is a novel coronavirus that causes coronavirus
disease 2019 (COVID-19). Cases from the outbreak were first identified in Wuhan China late
2019 and was classified as a pandemic by the World Health Organization (WHO) on March 11,
2020.5 SARS-CoV2 attacks lung cells through different entry points. In adults, the invasion of
the virus triggers the host’s immune response and initiates the body’s protective mechanisms but
may still lead to severe respiratory distress syndrome.6 COVID-19 can also attack ACE2
receptors located in vascular, renal, and gastrointestinal cells.6 The most common clinical
presentations of COVID-19 includes fever, fatigue, shortness of breath, and dry cough, however
gastrointestinal, cardiac, and renal systems symptoms may also occur.7 As of Sept 09, 2020, the
total number of deaths in the US is 195,184, and approximately 6,548,000 have been infected.8
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Pregnant women are more susceptible to respiratory infections, therefore influenza
vaccines are highly recommended during flu season.9 During pregnancy, women experience a
normal physiologic response of decreased pulmonary capacity and immunosuppression and thus
may be at greater risk for poor outcomes from COVID-19 infection.7 Even though only 16 deaths
among pregnant or postpartum women have been identified in the US, many cases of the
infection have been recorded with some resulting in severe illness, emergency cesarean sections,
and potential neonatal infection.7 The fear of either acquiring the disease, or the potential effects
on the fetus or newborn may lead to heightened anxiety and depression in this population.
The current widespread outbreak of COVID-19 has been found to be associated with
psychological distress and increased mental health symptoms including depression, anxiety, and
post-traumatic stress diagnoses in the general population but especially so in females.10, 11
Moreover, public health organizations worldwide anticipate increased anxiety and depression
rates and symptoms, especially in populations such as perinatal women, who are at increased risk
for PAD.12 Adverse effects of untreated PAD for mothers, infants, and families are well
documented and include physical, emotional, social, cognitive, and financial effects.13 Anxiety
and depressive symptoms in mothers during pregnancy are associated with shorter gestation, low
birth weight infants, adverse fetal and child neurodevelopment outcomes.14 Appropriate
interventions are much needed to address PAD in the best of times, but especially in the wake of
the COVID-19 pandemic. Because many perinatal women seek services in the primary care (PC)
setting, PC providers including nurse practitioners and nurse-midwives may benefit from
understanding the specific needs of this population, including the risk of exacerbated PAD in
light of the current pandemic. This article provides information for PC providers on the increased
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risks for PAD, and offers suggestions for clinical modifications to meet the mental health needs
of perinatal women during the SARS-COV-2 pandemic.

Perinatal Anxiety and Depression During COVID-19
The aggressive and deadly nature of COVID-19 has caused a significant public mental
health crisis in the US.15 The impact of the pandemic is becoming evident in social, economic,
social and political aspects of the US. The uncertainty, fear and high levels of stress around the
crisis are leading to increased mental health issues. A recent Kaiser Family Foundation poll
revealed that almost half of adults indicated a negative emotional impact of the pandemic due to
worry, stress, and anxiety.16
Pregnant women may be more vulnerable and more prone to adverse mental health
effects of such large-scale public health crises. A multi-center cross-sectional study was
conducted in China in the early phase of the outbreak to examine the impact of COVID-19 on
PAD.17 A total of 4124 pregnant women were screened with the Edinburgh Postnatal Depression
Scale (EPDS) before and after the announcement of the COVID-19 pandemic in China. The
comparison showed the participants had significantly higher rates of anxiety and depressive
symptoms (p = 0.02) after the announcement was made. Risk factors for perinatal anxiety and
depression were identified in the study, including being less educated, low income, poor family
or social support, and lack of physical activity. The results are consistent with other literature
findings. New mothers in northeastern Italy also reported significantly higher EPDS scores and
worsening depressive symptoms because of the fear of COVID-19 exposure and the quarantine
measures during the pandemic.18
Another source of anxiety for pregnant mothers is fear of potential harm to the unborn
child. Vertical transmission from mother to newborn during labor and birth has not been well
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documented but it cannot be ruled out.19,20 A recent case in France discovered the infectious
SARS-CoV2 agent in placental tissue and neonatal nasopharyngeal swabs leading the
researchers to conclude that transplacental transmission most likely occurred.21 Careful
monitoring of all patients is recommended for delivery with some hospitals testing all women
upon admission.22 If a woman is positive for COVID-19, isolation is recommended and some
suggest that neonates should be separated from infected mothers and caregivers to reduce
transmission.22,23
Though necessary for infection control and based upon maternal health status, isolation
immediately after birth may delay maternal infant attachment, suppress successful breastfeeding,
and increase maternal fear and anxiety.9 However, some institutions are allowing breastfeeding
of neonates by an infected mother if strict hygienic measures are adhered to such as handwashing
and wearing masks.24 Preterm birth and intrauterine growth restriction (IUGR) are the most
common adverse fetal events, but preeclampsia, cesarean section and perinatal death are also
higher in pregnant women with COVID-19.25 However, there is some empirical statistical
evidence that preterm births in the US may actually be reduced during COVID-19 though further
research is needed on this topic.26
The uncertainty around the features, symptoms and treatments of the novel coronavirus
and loss of supportive perinatal services causes elevated fear overall and concern for vertical
transmission and adverse pregnancy outcomes.7 Hospital tours and childbirth classes that have
historically helped birthing parents assuage concerns stemming from unfamiliar surroundings
and birth processes are now being canceled in order to maintain social distancing.27 Nursing and
medical staff from maternal and newborn units are often reassigned to emergency departments
and intensive care units to attend to COVID-19 related patients rendering perinatal units in some
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hospitals inadequate for care of non-COVID laboring and postpartum patients. All of these
changes and uncertainties may lead to more fear, anxiety, and depressive symptoms in women
who may already be at risk for PAD, and even cause otherwise low risk women to have
increased symptoms.
Furthermore, measures such as excluding birth partners from labor and birth, separating
newborns from infected mothers in the immediate postnatal period, restricting breastfeeding, and
emergent cesarean deliveries are common in perinatal care facilities in the attempt to control the
risk of cross-infection.27 This reduction in appropriate healthcare services, physical contact, and
bonding time between parents and neonates is expected to intensify PAD symptoms in perinatal
women.
To slow the spread of SARS-CoV2, governments worldwide have ordered different
versions of lockdown. The abrupt changes to everyday life have brought on additional hardship
and challenges for people in many different ways. In the US, staying home or “shelter-in-place”
(SIP) orders are enforced inconsistently throughout the US. Non-essential businesses are closed
and many companies mandate remote work for employees; however, many lower income
workers are not able to work from home. The aftermath of the SIP order is causing massive
temporary or permanent job loss. Unemployment rates reached as high as 14.7%, with
22,000,000 unemployed in April 2020 however August of that same year the rate was 8.4%.28 As
a result, many experience financial, food, and housing insecurity as well as social isolation which
increase the risk for intimate partner violence (IPV) and child maltreatment.29,30 Current data,
though limited, suggests that there has been increased reports and severity of violence against
women or IPV during the COVID 19 outbreak.31,32 Police reports collected in China during
February 2019 compared to February 2020 revealed IPV cases tripled during the lockdown.31
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Also, past epidemics such as Ebola and Zika resulted in increased incidences of IPV and
violence against women.33 Studies have shown that the COVID-19 pandemic can exacerbate the
contributing factors for IPV such as general stress, low income, and lack of access to social
networks and support.33
IPV is strongly associated with depression in perinatal women.34 The culmination of all
of these stressors and reduced ability to access usual coping strategies increase the risk for
perinatal women developing PAD during the COVID-19 pandemic. Fathers are also at risk for
PAD as well and if their symptoms are untreated, there may be increased marital conflict and
relationship disruption which may further lead to increased incidences of IPV.

Prevention
Because of the enormous shifts in society during the current pandemic, many perinatal
women may not feel a connection to others or experience the usual rights of passage during the
perinatal period such as therapeutic connection with healthcare providers, social interaction with
other pregnant women, and family member celebrations. To mitigate this lack of connection,
technology may be used to facilitate these human interactions. Group prenatal and postpartum
care via telehealth may help provide social interaction, networking, and reduce mild PAD
symptoms.35 Providing education to perinatal individuals and their families on symptoms of
PAD during pregnancy and the postpartum period may improve early detection and intervention
rates as well as normalize screening.

Intervention
Perinatal women experience hormonal, body image, sleep disturbances changes, and new
roles as pregnant and a new mother. Many new mothers experience normal “baby blues” that
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occur within the first 2 weeks postpartum but some may develop more severe symptoms of PAD.
Because the current pandemic may greatly increase the risk for perinatal fear, anxiety, and
depression, enhanced services are warranted. Interventions to address perinatal mental health
should remain high priority when caring for pregnant and postpartum women. Interventions may
include increased screening frequency, pharmacologic and nonpharmacologic treatments, and
use of telehealth as a treatment delivery modality. If left untreated, PAD has immediate and long
term effects on partners, fetal outcomes, and child health.

Screening
Consistent screening for perinatal mood and anxiety disorders has been identified as a
priority during a public health crisis.17 The American College of Obstetricians and Gynecologists
(ACOG) recommends screening for PAD at least once during the perinatal period and the
American Academy of Pediatrics recommends incorporating the Edinburgh Postnatal Depression
Scale into the 1-, 2-, 4- and 6-month well infant visits.36 Additionally, the USPSTF has called for
PAD screening, treatment, and referral though screening frequency is not specified, it is listed it
as a category B service which requires insurance coverage.37 Moreover, ACOG has
acknowledged the need for increased screening and services for perinatal women due to
emotional stressors encountered during the pandemic.38
Factors that improve screening outcomes are well documented by Long et al. who
suggest several strategies.36 Providing educational sessions on PAD to professionals who offer
services to perinatal women improves screening rates and early intervention. Including
information on suicide prevention, crisis intervention, treatment options, and screening
techniques enhances provider confidence and likelihood of screening, treatment, or referral.
Changes in the electronic health records (EHR) system to provide a “pop up” reminder to screen
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perinatal women further improves screening rates. Additionally, the use of simulation
educational interventions for healthcare professionals using standardized patients is another
factor that improves screening, treatment, and ultimately improves maternal and child health.36
The most commonly used depression screening tools are the Patient Health Questionnaire
(PHQ-9 and PHQ-2) and the Edinburgh Postnatal Depression Scale (EPDS).39 PHQ9 and PHQ2
are a set of concise and self-administered or provider-administered tools for assessing depression
with high sensitivity (88%) and specificity (88%) for major depressive disorders.39 The PHQ2
contains the first two items of the PHQ-9 assessing the degree to which an individual has
experienced depressed mood and anhedonia over the past two weeks.39 Individuals who screen
above the cut off for the PHQ-2 should proceed to PHQ-9 and be further evaluated to determine
if they meet diagnostic criteria for depression. The PHQ incorporates DSM-IV depression
criteria as well as major depressive symptoms.
The EPDS is a questionnaire developed to detect postpartum depression (PPD) and has
also been validated in prenatal populations. It is composed of 10 questions and each question is
given a score of 0 to 3 with maximum score 30. Any score 13 or above is likely to indicate PPD
and the individual should be evaluated further for diagnosis of depression. The EPDS focuses on
two domains of negative affect: depressive symptoms and anxiety and has a sensitivity rate of
90% and specificity rate of 90% at an optimal cutoff score.37,40
Both PHQ-2 and -9 and the EPDS can be easily self-administered remotely and online, or
given by the provider. Both tools are available in a variety of languages. With utilization of the
existing tools, providers may assume the role of advocate to prioritize increased screening
frequency during the current pandemic to improve prevention and early intervention for
improved outcomes for mother, infant, and family. Screening for bipolar disorder and substance
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use disorder must be included using validated tools such as the Mood Disorders Questionnaire
and the CAGE-AID.12,41 Prompt referral to a psychiatric care provider for results above the cut
off is required.
Treatment
Standard of care guidelines for treatment of PAD include pharmacologic and nonpharmacologic interventions. Mindfulness-based cognitive group therapy, face-to-face cognitive
behavior therapy (CBT) programs, internet-delivered cognitive behavioral programs, and
combined pharmacologic-psychological programs (medication and CBT) demonstrate similar
improvements of anxiety and depression symptoms in the perinatal women.42 Other treatment
modalities that are reserved for severe cases of perinatal depression and are rarely used in
primary care include: repetitive transcranial magnetic stimulation (rTMS) or electroconvulsive
therapy.43 (See Table 1 for full list of treatment modalities.)
CBT is a type of psychological treatment that has been proven to be effective for a range
of problems including PAD. CBT involves efforts to change an individual's thinking and
behavior patterns. Based on several core principles that psychological problems are partially
based on faulty or unhelpful ways of thinking and learned patterns of unhelpful behavior,
individuals can learn more effective ways of coping hence relieving symptoms.44
Mindfulness-based cognitive behavioral therapy (MBCT) focuses on mindfulness and
meditation in addition to CBT interventions. MBCT is widely used and found effective in
treatment of general depression and many other mental health problems.45 It is essential for one
to know the skills needed to cope with stress and emotional challenges and the techniques used
in MBCT are easy to learn and can be used in a variety of settings to reduce symptoms. By using
meditation and breathing techniques, MBCT helps an individual become more aware of their
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modes of mind, thoughts, and emotions thus reducing symptoms of anxiety and depression and
ultimately improving maternal, infant, and family health.45 Psychiatric mental health nurse
practitioners (PMHNP) and therapists can provide these services to groups or individuals.
In addition to psychotherapy, pharmacologic interventions are also useful in treatment of
PAD. Anxiolytics, especially benzodiazepines, are rarely used in perinatal women because of the
adverse effects to the fetus (preterm birth) and breastfed infant (sedation) from maternal use.46
Selective serotonin reuptake inhibitors (SSRIs) are the main class of drugs in treatment for PAD
in the PC setting because of their favorable adverse effect profile and overdose safety compared
with tricyclic antidepressants which have a significant adverse side effect profile.47 Pregnant and
lactating women need special consideration in the use of medications because of risks to the
fetus and infant. Careful consideration of the risks, benefits, expected outcomes, and alternatives
to medication use must be included. Also, a single medication is favored over multiple ones
during pregnancy and lactation to minimize exposure to the fetus or infant. Shared decisionmaking is recommended to assist perinatal women in making informed treatment choices.48
Though all SSRIs are excreted in breastmilk, some have a lower adverse effect profile
than others. Among SSRIs, sertraline and paroxetine are the first-line medications recommended
for breastfeeding mothers because of their minimal risk for infants.49 Infant serum levels of
sertraline and paroxetine are not detectable; in contrast, fluoxetine may be present in higher
levels in breast milk and breastfed infants.50 During pregnancy, sertraline or escitalopram is
preferred because of a lower risk for adverse fetal effects and neonatal abstinence syndrome
(NAS). However, paroxetine is not recommended because of the increased risk for
teratogenicity in the first trimester and NAS if used in third trimester.49,50 PC providers should
consider referral to a psychiatric care services if symptom improvement does not occur in about
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8 weeks or if there are symptoms of psychosis, manic features, or suicidal ideation.51 PMHNPs
can provide talk therapy and consultation on medication use in coordination with PCPs.
In some instances of severe postpartum depression or when SSRIs are not tolerated,
brexanolone may be given IV but this treatment requires hospitalization and is not given in
primary care.52 Though symptoms usually resolve within 2-5 days with brexanolone use, the side
effect profile is considerable. Distribution in the US is limited to registry enrollees and the drug
carries a “black box warning” because of the risk of loss of consciousness, sedation, and
tachycardia.53
Telehealth
The majority of primary care clinics in the US have increased incorporation of telehealth
in daily practice. Telehealth is a feasible alternative to in person visits during infectious disease
outbreaks such as COVID-19 as it reduces in-person interactions in clinics mitigating the risks of
infection. The efficacy of telehealth has been evaluated and promoted for the perinatal
population in synchronous or asynchronous formats.38 Telehealth modalities may include
synchronous or “real time” health services through videoconferencing or telephone,
asynchronous for delivery at a later time, or m-health which involves healthcare messaging.38
A variety of telehealth modalities may be used including short message service (SMS) or
“text messages,” mobile phone apps, videos for m-health, remote monitoring devices for
asynchronous monitoring and internet-delivered interventions such a video conferencing.54,55
(See Table 2 for telehealth modalities.) Telehealth has been found to be effective in reinforcing
positive health behaviors and remote monitoring (blood pressure and blood glucose in perinatal
women) and as a result, significantly reduced in-person medical visits.54 Additional uses include
re-enforcing educational material on self-care to improve perinatal mental health.
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Given the increased demand for mental health services and the reduced availability of in
person medical services during the pandemic, the use of telehealth and digital mental health
resources are a promising and feasible alternative. Additionally, the use of telehealth visits with
PMHNPs or therapists can supplement care for these conditions by PC or obstetrical care
providers and serve as a bridge between the two. Utilization of digital resources may also free up
some PC providers to provide care for other more acute health conditions.55 Because of the
validation of mental health service delivery in other populations, and the need to mitigate
COVID-19 infection, the use of synchronous tele-health visits for mental health service delivery
in the perinatal population may be a viable option.
However, the use of telehealth may not be an option for those who do not have access to
broadband Internet, computers or smartphones or those who do not know how to operate high
technology services or devices. The Federal Communications Commission (FCC) estimates that
over 21 million US residents, especially in the rural communities, do not have access to
broadband Internet.56 Despite government efforts to bridge the broadband gap, much work is still
needed to provide Internet and telehealth access throughout the US.56 Lack of broadband Internet
also means that many individuals may not have the ability to work remotely.
Lack of privacy for access to telehealth may be an additional barrier for perinatal women
during SIP. Children and others may be at home during SIP, creating demands for care and
limiting the ability to locate a quiet place for a telehealth visit. For those experiencing IPV, the
ability to have privacy away from the perpetrator for a telehealth visit may be a source for
discord in the relationship and further violence.57
Learning opportunities and access to all health care services may also be limited, which
may lead to further isolation and mental health stressors. In efforts to alleviate these problems,
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some services may be provided by telephones. Telephones are much more readily available in
US households and can serve as a reliable mode of telehealth, though both individual and the
provider may not have as much information from telephone visits as compared to video
conference telehealth visits. Healthcare providers must evaluate all the options available and
utilize resources to maximize services for perinatal women to improve health outcomes.

Summary
The COVID-19 pandemic has the potential to greatly increase the level of anxiety and
stress among perinatal women. Pregnant and lactating women are more vulnerable to external
stressors such as a major public health crisis and are at higher risk of developing PAD.
Prevention, early identification, and treatment of PAD are essential during the pandemic due to
the negative effect on both maternal and child outcomes and the significant impact if left
unscreened and untreated.
Using technology to increase education about the symptoms and risks associated with
PAD may be a viable option for many perinatal women. Increasing screening for PAD in this
population is crucial to identify risk factors and symptoms so that early intervention can be
initiated. Existing screening tools are self-administered questionnaires that are freely accessible
through the internet or provided as part of routine prenatal care services. For those who live in
rural areas and do not have access to the Internet, phone screening can be an equally effective
and reliable alternative. Once a screen result is above the cut-off, then providers can initiate
individualized treatment options and offer additional resources. Though screening tools are not
diagnostic, they can be used to identify those at highest risk for PAD. Further evaluation is
needed to arrive at a diagnosis and treatment plan.
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Clients should be encouraged to participate in the decision-making process as they are the
best advocates for themselves and their families. The ultimate goal is to improve both maternal
and child health outcomes by minimizing the development of PAD and alleviating the symptoms
by increased screening and education using technology.

Table 1
Treatment of Perinatal Anxiety and Depression

Categories

Condition

Type of Intervention

Notes

Nonpharmacologic:
Professional
intervention

Anxiety and
Depression

Cognitive
Behavioral Therapy

-

Talk therapy
Reframing ways of thinking
Improving coping skills
Change patterns of thinking and behaviors

Anxiety and
Depression

Mindfulness-based
Cognitive
Behavioral Therapy

-

CBT and meditation combination
Breathing techniques
Awareness skills

Nonpharmacologic:
Client
intervention

Anxiety and
Depression

Self -care

-

Support groups
Family support
Yoga
Meditation
Exercise
Adequate sleep
Nutrition and vitamins

Pharmacologic
therapy

Depression

Selective Serotonin
Reuptake Inhibitor
(SSRI)

-

Sertraline (pregnancy and lactation)
Paroxetine (lactation only)
Fluvoxamine (pregnancy and lactation)
Less adverse effects and safer profile
May take 2-3 weeks for symptom
improvement

Anxiety

Selective Serotonin
Reuptake Inhibitor
(SSRI)

-

Sertraline (pregnancy and lactation)
Escitalopram (pregnancy only)
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Table 2
Modalities of Telehealth

Type of Telehealth

Delivery Format

Applications

Advantages and Disadvantages

Advantages:
- Immediate, clear, and accurate
information in real-time
- Allows effective patient-physician
verbal exchanges
- Comparable health outcomes
- Limited exposure to clinics/other
patients and lower risk of
COVID-19 infections
Disadvantages:
- Ethical concern of absence of
face-to-face relationship or
encounters
- Limited physical examination
- Requires quiet and private
environment
- Patient-physician relationship
may be compromised

Videoconferencing,
Telephone

Synchronous

Primary care and
Obstetrics

Recordings (video and
audio)

Asynchronous

Educational and
Support
Intervention

Advantages:
- Easy and flexible access to
educational material
Disadvantages:
- No immediate resources for
questions

SMS
Smartphone apps
On-line Chats

Asynchronous

Educational and
Support
Intervention

Advantages:
- Effective and easier access to
timely information and support
Disadvantages:
- Requires digital devices and
Internet
- Lacks human connection

Table 3 Additional Resources for Maternal Mental Health
Name of Resource
The International Marcé
Society for Perinatal Mental
Health

Content
-

Webpage
Advocates for prenatal and
postpartum mental health for
mothers, fathers and infants.

https://marcesociety.com/
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COVID-19 related maternal mental
health resources

-

Educational presentations
Books, DVDs

-

COVID-19 related maternal mental
health resources
Maternal mental health/wellness
program
Informative patient guides articles

https://womensmentalhealth.org
/

Educational books, DVDs,
brochures
PSI support groups
PSI guidebooks
State Perinatal Psychiatry Access
Programs
Medication resources

https://www.postpartum.net/

Marcé of North America

The Center for Women’s
Mental Health

Postpartum Support
International

18

-

https://marcesociety.com/region
al-groups/marce-of-northamerica/
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